Bristol Myers Squibb Appoints Sandra Orta as General Manager for Spain and Portugal, Boosting Biopharmaceutical Strategy

Bristol Myers Squibb (BMS) signs talent at Almirall. The biopharmaceutical has appointed Sandra Orta as the new general manager for Spain and Portugalfrom the Catalan pharmaceutical company, as announced on Monday by BMS through a statement.

Orta’s arrival will help boost BMS’s strategy as a biopharmaceutical company that develops innovative medicines in both countries. The new head of the group in Spain and Portugal succeeds Roberto Úrbez, who has directed the Spanish subsidiary for the last nine years and who has announced his retirement from the company.

Before joining the head of BMS in Spain and Portugal, Orta was head of marketing at Almirall, where he led global strategy and marketing, digital transformation and new product planning. Previously, between 2019 and 2022, the executive was CEO of South Africa and head of the Roche Diagnostic Management Center.

Bristol Myers Squibb hires an expert with more than twenty years of experience in the sector

The new director of BMS Spain and Portugal has more than twenty years of experience leading companies in the pharmaceutical, diagnostic, biotechnological sector and non-governmental organizations, both in Europe, the United States, as well as Latin America, the Middle East, Sub-Saharan Africa and Asia.

Orta has a degree in Pharmacy from the University of Barcelona (UB), in addition to having a master’s degree in Business Administration and Pharmaceutical Marketing from the Idec of the Universitat Pompeu Fabra in Barcelona.

The incorporation of Orta to BMS coincides with an important moment for the company, since the subsidiary in Spain and Portugal prepares the launch of several products in therapeutic areas with unmet medical needs such as oncology, immune-mediated diseases and cardiovascular diseases.

The company entered 11,337 million dollars in the first quarter of 2023, 3% more than a year ago

Bristol Myers-Squibb was founded in 1887 and is headquartered in New York.. The company is focused on the development of cancer treatments, immunotherapy, cardiology and fibrosis.

The company’s data in the first quarter of 2023 shows revenues of 11,337 million dollars, compared to 11,648 million dollars in 2022, which represents a year-on-year increase of 3%.

Sales of the company’s products in the United States reached a total of 5,700 million dollars, representing an interannual increase of 11%. In the international sector, sales per product reached 2,883 million euros, while in all the group’s markets sales per product stood at 8,625 million euros.